Integrative Multi-omics analysis of Multiple Myeloma in the MIDAS trial.
The project aims to develop a multi-omics classification of multiple myeloma by integrating genomics, transcriptomics, and epigenomics data, and identify molecular predictors of high-risk disease in newly diagnosed MM patients treated with Isa-KRD quadruplet therapy, using samples from the MIDAS trial.
The project is based on the expertise of the ICAGEN team and uses the computing and storage resources of the GLiCID computing infrastructure.
IM3MIDAS is funded by the Intergroupe Francophone du Myélome (IFM) and the ILIAD SIRIC (INCa-DGOS-INSERM-ITMO Cancer_18011)
